Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Pain management

Fibromyalgia drugs are 'as good as it gets' in chronic pain

Nature Reviews Rheumatology volume 6, pages 439–440 (2010)Cite this article

Subjects

A systematic review of randomized controlled trials reveals some differences in the effects and indications of the three pharmalogical treatments for fibromyalgia. What can prescribing physicians glean from the results?

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on SpringerLink
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Häuser, W., Petzke, F. & Sommer, C. Comparative efficacy and harms of duloxetine, milnacipran, and pregabalin in fibromyalgia syndrome. J. Pain 11, 505–521 (2010).

    Article  Google Scholar 

  2. Goldenberg, D. L. et al. Durability of therapeutic response to milnacipran treatment for fibromyalgia. Results of a randomized, double-blind, monotherapy 6-month extension study. Pain Med. 11, 180–194 (2010).

    Article  Google Scholar 

  3. Williams, D. A. & Clauw, D. J. Understanding fibromyalgia: lessons from the broader pain research community. J. Pain 10, 777–791 (2009).

    Article  Google Scholar 

  4. Kroenke, K., Krebs, E. E. & Bair, M. J. Pharmacotherapy of chronic pain: a synthesis of recommendations from systematic reviews. Gen. Hosp. Psychiatry 31, 206–219 (2009).

    Article  Google Scholar 

  5. Bjordal, J. M., Klovning, A., Ljunggren, A. E. & Sløordal, L. Short-term efficacy of pharmacotherapeutic interventions in osteoarthritic knee pain: a meta-analysis of randomised placebo-controlled trials. Eur. J. Pain 11, 125–138 (2007).

    Article  CAS  Google Scholar 

  6. Chou, R. & Huffman, L. H. Nonpharmacologic therapies for acute and chronic low back pain: a review of the evidence for an American Pain Society/American College of Physicians clinical practice guideline. Ann. Intern. Med. 147, 492–504 (2007).

    Article  Google Scholar 

  7. Williams, D. A. in Fibromyalgia & Other Central Pain Syndromes (eds Wallace, D. J. & Clauw, D. J.) 343–352 (Lippincott Williams & Wilkins, Philadelphia, 2005).

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Anesthesiology, University of Michigan Medical School, 24 Frank Lloyd Wright Drive, PO Box 385, Ann Arbor, 48106, MI, USA

    Daniel J. Clauw

Authors
  1. Daniel J. Clauw
    View author publications

    You can also search for this author in PubMed Google Scholar

Ethics declarations

Competing interests

The author has acted as a consultant for Cypress Biosciences, Forest Laboratories, Jazz Pharmaceuticals, Lilly, Merck, Pfizer and UCB, and has received research support from Cypress Biosciences, Forest Laboratories and Pfizer.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Clauw, D. Fibromyalgia drugs are 'as good as it gets' in chronic pain. Nat Rev Rheumatol 6, 439–440 (2010). https://doi.org/10.1038/nrrheum.2010.120

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrrheum.2010.120

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing